Rare and Orphan Diseases

Episodes 1-15 of 24

• 

  RestartResume

  IgAN Insights: The Potential Role of the Complement System in Disease Progression

  Medical Industry Feature

  IgAN Insights: The Potential Role of the Complement System in Disease Progression

  • 

    

    Jean Francis, MD

    Peer

• 

  RestartResume

  Identifying Patients at High-Risk for IgAN Progression: Key Factors to Know

  Medical Industry Feature

  Identifying Patients at High-Risk for IgAN Progression: Key Factors to Know

  • 

    

    Jean Francis, MD

    Peer

  • 

    

    Anthony Chang, MD

    Peer

• 

  RestartResume

  The CLL Patient Journey: From Diagnosis to Initial Treatment

  Medical Industry Feature

  The CLL Patient Journey: From Diagnosis to Initial Treatment

  • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Alexey Danilov, MD, PhD

    Peer

  • 

    

    Brian Koffman, MDCM

    Peer

• 

  RestartResume

  Navigating CLL Treatment: Patient Preferences and Shared Decision-Making

  Medical Industry Feature

  Navigating CLL Treatment: Patient Preferences and Shared Decision-Making

  • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Alexey Danilov, MD, PhD

    Peer

  • 

    

    Brian Koffman, MDCM

    Peer

• 

  RestartResume

  Managing the Complexities of Acute Graft-Versus-Host Disease: Current Challenges and Unmet Needs

  Medical Industry Feature

  Managing the Complexities of Acute Graft-Versus-Host Disease: Current Challenges and Unmet Needs

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

    Peer

  • 

    

    Miguel-Angel Perales, MD

    Peer

  • 

    

    Anna Sureda, MD, PhD

    Peer

• 

  RestartResume

   Advancements in Understanding ALS Treatment

  Medical Industry Feature

   Advancements in Understanding ALS Treatment

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

    Peer

  • 

    

    Gustavo Suarez Zambrano, MD

    Peer

• 

  RestartResume

  Gene Therapy: Changing the Landscape of Hemophilia B Care

  Medical Industry Feature

  Gene Therapy: Changing the Landscape of Hemophilia B Care

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Tammuella Chrisentery-Singleton, MD

    Peer

• 

  RestartResume

  From Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice

  Medical Industry Feature

  From Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Thomas Brannagan III, MD

    Peer

  • 

    

    Marcus Anthony Urey, MD

    Peer

• 

  RestartResume

  Investigating a gMG Therapy, Part 1: The MG-ADL Results

  Medical Industry Feature

  Investigating a gMG Therapy, Part 1: The MG-ADL Results

  • 

    

    Christyn Edmundson, MD

    Peer

• 

  RestartResume

  Investigating a gMG Therapy, Part 2: The Secondary Endpoint Results, Including MG Symptoms PRO

  Medical Industry Feature

  Investigating a gMG Therapy, Part 2: The Secondary Endpoint Results, Including MG Symptoms PRO

  • 

    

    Christyn Edmundson, MD

    Peer

• 

  RestartResume

  Investigating a gMG Therapy, Part 3: Results from the Extension Studies

  Medical Industry Feature

  Investigating a gMG Therapy, Part 3: Results from the Extension Studies

  • 

    

    Christyn Edmundson, MD

    Peer

• 

  RestartResume

  SCIg for Patient-Centric Care: Combining Experience with Innovation

  Medical Industry Feature

  SCIg for Patient-Centric Care: Combining Experience with Innovation

  • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Elena Perez, MD

    Peer

• 

  RestartResume

  Uncovering Unmet Needs in ATTR Amyloidosis

  Medical Industry Feature

  Uncovering Unmet Needs in ATTR Amyloidosis

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

    Peer

  • 

    

    Nitasha Sarswat, MD

    Peer

• 

  RestartResume

  Unraveling Hereditary ATTR Amyloidosis: Key Variants and Clinical Insights

  Medical Industry Feature

  Unraveling Hereditary ATTR Amyloidosis: Key Variants and Clinical Insights

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Nitasha Sarswat, MD

    Peer

  • 

    

    Thomas Brannagan III, MD

    Peer

• 

  RestartResume

  Clinical Insights into Higher-Risk MDS: Treatment Goals and Strategies

  Medical Industry Feature

  Clinical Insights into Higher-Risk MDS: Treatment Goals and Strategies

  • 

    

    Gates B. Colbert, MD

    Peer

  • 

    

    Uma Borate, MD

    Peer

  • 

    

    James Dugan, MD

    Peer

• 1
• 2
• Next